Skip to content

Evaluation of the effect of Raccutane on nasal skin thickness in rhinoplasty patients

Evaluation of the effect of Raccutane on nasal skin thickness in rhinoplasty patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170120032069N6
Enrollment
42
Registered
2020-06-02
Start date
2020-03-20
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasal skin thickness in Rhinoplasty patients..

Interventions

Intervention 1: Intervention group: isotretinoin, brand name Raccutane(produced by the German company Roche), is started at a dose of 0.5 mg / kg / day in the intervention group for 6 months. Interven

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients who are candidates for rhinoplasty. Have a moderate or thick thickness of the nasal skin in the Obaghi skin pinch test. Have an age range of 18 to 60 years.

Exclusion criteria

Exclusion criteria: The patients with allergy to Vit A. Women who are likely to become pregnant within the next year. Patients who have a history of rhinoplasty.

Design outcomes

Primary

MeasureTime frame
Nasal Skin Thickness in patients with rhinoplasty. Timepoint: Measuring the thickness of the derm in the skin of the nose and soft tissue in the three areas of Tip and Supratip and Keystone before the intervention and also three and six months after the intervention. Method of measurement: Measurement of dermal thickness with sonography.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZohre Kaedi

Tehran University of Medical Sciences

zohrekaedi@gmail.com+98 21 6670 6106

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026